Search | Clinical Trials Finder

Conditions: Delirium
Interventions: Family Support System, HELP Support System; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 70 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: Oral treprostinil, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Alopecia, Male Pattern Hair Loss
Interventions: KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826; Drug
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Fountain Valley, California • Hialeah, Florida • Hialeah Gardens, Florida + 7 more

Conditions: Bacterial Infections
Interventions: KSP-1007, Placebo:0.9% sodium chloride, Meropenem; Drug · Other
Lead sponsor: Sumitovant Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Proctitis, Proctosigmoiditis
Interventions: Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 62
States / cities: Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more

Conditions: Healthy Subjects
Interventions: Exenatide, Moxifloxacin, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Covid19, Multisystem Inflammatory Syndrome in Children
Interventions: Larazotide Acetate, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Month to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: AZD6765, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 24 more

Conditions: Celiac Disease
Interventions: Larazotide acetate, Placebo, Gluten 900 mg; Drug · Dietary Supplement
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 14
States / cities: Orange, California • Topeka, Kansas • Lexington, Kentucky + 11 more

Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions: NBI-921352, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more

Conditions: Schizophrenia
Interventions: Placebo, Tolcapone; Other · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Moderate to Severe Atopic Dermatitis
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Bryant, Arkansas • Fountain Valley, California • Los Angeles, California + 22 more

Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Insulin Resistance
Interventions: (PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose, Placebo; Drug · Other
Lead sponsor: EncuraGen, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psoriasis
Interventions: Drug: LYC-30937-EC, Placebo; Drug
Lead sponsor: Lycera Corp.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Carmel, Indiana • Andover, Massachusetts • Fridley, Minnesota + 4 more

Conditions: Sickle Cell Disease
Interventions: Mitapivat Matched Placebo, Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan • Flowood, Mississippi

Conditions: Diabetic Peripheral Neuropathy
Interventions: Erchonia® FX-635™, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Covid19
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 7 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 55
States / cities: Birmingham, Alabama • Fullerton, California • La Palma, California + 34 more

Conditions: Parkinson's Disease
Interventions: nicotine, placebo comparator; Drug · Other
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more

Conditions: Sudan Virus Disease
Interventions: rVSVΔG-SUDV-GP, Placebo; Biological · Other
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Lenexa, Kansas • Boston, Massachusetts

Conditions: Cataract
Interventions: MELT-300, Midazolam alone, Ketamine alone, Placebo; Drug
Lead sponsor: Melt Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota

Conditions: Ankylosing Spondylitis
Interventions: AIN457, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 10
States / cities: Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 6 more

Conditions: Stroke, Cerebral Ischemia, Brain Infarction
Interventions: Ancrod (Viprinex), Placebo; Biological · Drug
Lead sponsor: Neurobiological Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 39
States / cities: Chico, California • Fresno, California • La Mesa, California + 32 more

Search by objective public record fields.

Recommendations and Alerting for Delirium Alleviation in Real-Time (RADAR)

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

AT1001 for the Treatment of COVID-19 Related MIS-C

AZD6765 Severe Major Depressive Disorder (MDD) IV

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Clinical Trial of Tolcapone for Cognition in Schizophrenia

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke